These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 15535312)

  • 1. [Relationship between overexpression of HER-2/neu protein and prognosis in epithelial ovarian cancer].
    Sasaki N; Takano M; Kudou K; Kita T; Kikuchi Y
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():582-6. PubMed ID: 15535312
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma.
    Sasaki N; Kudoh K; Kita T; Tsuda H; Furuya K; Kikuchi Y
    J Obstet Gynaecol Res; 2007 Feb; 33(1):17-23. PubMed ID: 17212661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy for cancer: the HER-2/neu and Herceptin story.
    Ross JS; Gray GS
    Clin Leadersh Manag Rev; 2003; 17(6):333-40. PubMed ID: 14692077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [HER-2 diagnostics].
    Bánkfalvi A
    Magy Onkol; 2002; 46(1):11-5. PubMed ID: 12050677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of HER-2 in ovarian carcinomas.
    Hellström I; Goodman G; Pullman J; Yang Y; Hellström KE
    Cancer Res; 2001 Mar; 61(6):2420-3. PubMed ID: 11289108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer.
    Lesniak D; Xu Y; Deschenes J; Lai R; Thoms J; Murray D; Gosh S; Mackey JR; Sabri S; Abdulkarim B
    Cancer Res; 2009 Nov; 69(22):8620-8. PubMed ID: 19887601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
    Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ
    Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
    Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
    Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Her-2/neu assessment for gastric carcinoma: validation of scoring system.
    Mrklic I; Bendic A; Kunac N; Bezic J; Forempoher G; Durdov MG; Karaman I; Prusac IK; Pisac VP; Vilovic K; Tomic S
    Hepatogastroenterology; 2012; 59(113):300-3. PubMed ID: 22260838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of HER-2/neu in uterine serous papillary cancer.
    Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
    Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
    Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
    Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside.
    Hanna W; Kahn HJ; Trudeau M
    Mod Pathol; 1999 Aug; 12(8):827-34. PubMed ID: 10463486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER-2/neu expression in primary and metastatic breast cancer.
    Lower EE; Glass E; Blau R; Harman S
    Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test.
    Scheurle D; Jahanzeb M; Aronsohn RS; Watzek L; Narayanan R
    Anticancer Res; 2000; 20(3B):2091-6. PubMed ID: 10928158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer.
    Agus DB; Bunn PA; Franklin W; Garcia M; Ozols RF
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):53-63; discussion 92-100. PubMed ID: 11236029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
    Bunn PA; Helfrich B; Soriano AF; Franklin WA; Varella-Garcia M; Hirsch FR; Baron A; Zeng C; Chan DC
    Clin Cancer Res; 2001 Oct; 7(10):3239-50. PubMed ID: 11595720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.
    Schmidt C
    J Natl Cancer Inst; 2011 Jan; 103(2):87-9. PubMed ID: 21191114
    [No Abstract]   [Full Text] [Related]  

  • 18. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
    Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma.
    Mimura K; Kono K; Hanawa M; Kanzaki M; Nakao A; Ooi A; Fujii H
    Clin Cancer Res; 2005 Jul; 11(13):4898-904. PubMed ID: 16000588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients.
    Altundag O; Altundag K; Ozcakar B; Silay YS
    Lung Cancer; 2005 Aug; 49(2):279-80. PubMed ID: 16022924
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.